107.51
price down icon2.47%   -2.72
after-market アフターアワーズ: 107.75 0.24 +0.22%
loading
前日終値:
$110.23
開ける:
$109.69
24時間の取引高:
11.68M
Relative Volume:
1.63
時価総額:
$133.89B
収益:
$28.75B
当期純損益:
$480.00M
株価収益率:
290.57
EPS:
0.37
ネットキャッシュフロー:
$10.31B
1週間 パフォーマンス:
-5.68%
1か月 パフォーマンス:
-0.13%
6か月 パフォーマンス:
+28.14%
1年 パフォーマンス:
+46.45%
1日の値動き範囲:
Value
$105.80
$109.72
1週間の範囲:
Value
$105.80
$115.47
52週間の値動き範囲:
Value
$62.07
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
名前
Gilead Sciences Inc
Name
セクター
Healthcare (1167)
Name
電話
(650) 574-3000
Name
住所
333 LAKESIDE DR, FOSTER CITY, CA
Name
職員
17,600
Name
Twitter
@GileadSciences
Name
次回の収益日
2025-02-11
Name
最新のSEC提出書
Name
GILD's Discussions on Twitter

GILD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
107.51 133.89B 28.75B 480.00M 10.31B 0.37
Drug Manufacturers - General icon
LLY
Lilly Eli Co
837.01 751.78B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
ABBV
Abbvie Inc
212.25 374.70B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
79.00 350.69B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
JNJ
Johnson Johnson
162.99 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
MRK
Merck Co Inc
94.02 251.88B 64.17B 17.12B 18.10B 6.73

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-04 繰り返されました Oppenheimer Outperform
2025-02-18 アップグレード Deutsche Bank Hold → Buy
2025-02-13 アップグレード DZ Bank Hold → Buy
2025-01-10 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-12-10 再開されました BofA Securities Buy
2024-11-15 開始されました Wolfe Research Outperform
2024-11-14 開始されました Citigroup Buy
2024-11-08 ダウングレード Maxim Group Buy → Hold
2024-10-21 アップグレード Leerink Partners Market Perform → Outperform
2024-10-17 開始されました Bernstein Outperform
2024-10-07 アップグレード Wells Fargo Equal Weight → Overweight
2024-07-08 アップグレード Raymond James Mkt Perform → Outperform
2024-05-01 繰り返されました Maxim Group Buy
2024-04-24 アップグレード HSBC Securities Reduce → Hold
2024-02-22 ダウングレード Truist Buy → Hold
2023-11-09 開始されました Deutsche Bank Hold
2023-09-08 アップグレード BofA Securities Neutral → Buy
2023-09-06 開始されました HSBC Securities Reduce
2023-07-24 繰り返されました Barclays Equal Weight
2023-05-16 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-28 再開されました Piper Sandler Overweight
2023-01-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2022-12-13 再開されました BofA Securities Neutral
2022-12-09 ダウングレード DZ Bank Buy → Hold
2022-10-31 アップグレード Barclays Underweight → Equal Weight
2022-10-28 繰り返されました BMO Capital Markets Market Perform
2022-10-28 繰り返されました Cowen Outperform
2022-10-28 繰り返されました JP Morgan Overweight
2022-10-28 繰り返されました Jefferies Buy
2022-10-28 アップグレード Piper Sandler Neutral → Overweight
2022-10-28 繰り返されました RBC Capital Mkts Outperform
2022-10-28 アップグレード Truist Hold → Buy
2022-10-28 繰り返されました Wells Fargo Equal Weight
2022-10-04 アップグレード JP Morgan Neutral → Overweight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-02-28 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-02-02 繰り返されました BMO Capital Markets Outperform
2022-02-02 繰り返されました BofA Securities Neutral
2022-02-02 繰り返されました RBC Capital Mkts Outperform
2022-02-02 繰り返されました Truist Hold
2022-02-02 繰り返されました Wells Fargo Equal Weight
2022-01-28 アップグレード Argus Hold → Buy
2022-01-06 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-12-09 再開されました Wells Fargo Equal Weight
2021-12-06 開始されました Goldman Neutral
2021-11-19 アップグレード BMO Capital Markets Market Perform → Outperform
2021-11-19 再開されました Piper Sandler Neutral
2021-10-20 再開されました Cowen Outperform
2021-07-30 繰り返されました BMO Capital Markets Market Perform
2021-07-30 繰り返されました RBC Capital Mkts Outperform
2021-04-01 アップグレード Bernstein Mkt Perform → Outperform
2021-03-30 アップグレード Redburn Neutral → Buy
2021-01-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-11-03 再開されました Morgan Stanley Equal-Weight
2020-10-28 開始されました UBS Neutral
2020-09-30 再開されました Jefferies Buy
2020-09-15 アップグレード Maxim Group Hold → Buy
2020-07-31 繰り返されました Credit Suisse Neutral
2020-07-31 繰り返されました Morgan Stanley Equal-Weight
2020-07-31 繰り返されました Piper Sandler Overweight
2020-07-31 繰り返されました RBC Capital Mkts Outperform
2020-07-31 繰り返されました SunTrust Hold
2020-07-31 繰り返されました Wells Fargo Equal Weight
2020-07-20 アップグレード Credit Suisse Underperform → Neutral
2020-06-03 アップグレード SVB Leerink Mkt Perform → Outperform
2020-05-26 アップグレード SunTrust Sell → Hold
2020-05-01 ダウングレード JP Morgan Overweight → Neutral
2020-05-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-01 ダウングレード SunTrust Hold → Sell
2020-04-27 ダウングレード UBS Buy → Neutral
2020-04-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-04-20 ダウングレード Wells Fargo Overweight → Equal Weight
2020-04-17 ダウングレード CFRA Hold → Sell
すべてを表示

Gilead Sciences Inc (GILD) 最新ニュース

pulisher
Mar 19, 2025

Gilead stock falls on report of HIV prevention cuts - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Stock Dives On A Devastating Potential Call From HHS - Investor's Business Daily

Mar 19, 2025
pulisher
Mar 19, 2025

Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts - Investing.com Canada

Mar 19, 2025
pulisher
Mar 19, 2025

Citi maintains Gilead stock Buy rating, $125 target amid HIV funding fears - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

BMO reiterates Gilead stock with $115 target amid HIV funding concerns - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies - CSRwire.com

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences Stock Slips on Possible HIV Funding Cut - Schaeffers Research

Mar 19, 2025
pulisher
Mar 19, 2025

Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In - Insider Monkey

Mar 19, 2025
pulisher
Mar 19, 2025

Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025' - StreetInsider.com

Mar 19, 2025
pulisher
Mar 19, 2025

The Trump Administration Wants to Cut Funding for HIV Prevention. Why Gilead Stock Is Falling. - Barron's

Mar 19, 2025
pulisher
Mar 19, 2025

Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention - Markets Insider

Mar 19, 2025
pulisher
Mar 19, 2025

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead slides as Trump administration puts HIV prevention funds under review - TradingView

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget - The Wall Street Journal

Mar 19, 2025
pulisher
Mar 19, 2025

Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts - Value the Markets

Mar 19, 2025
pulisher
Mar 18, 2025

Gilead, GSK could be impacted by potential HHS HIV prevention cuts - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Gilead Sciences CFO Andrew Dickinson sells $276,325 in stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Gilead Sciences stock falls on potential HIV funding cuts By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 18, 2025

Gilead Sciences stock falls on potential HIV funding cuts - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Unpacking the Latest Options Trading Trends in Gilead Sciences - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Gilead Sciences (GILD): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Coronavirus: La Commission européenne signe un accord avec Gilead sur le remdesivir - Reuters

Mar 17, 2025
pulisher
Mar 17, 2025

Is Gilead Sciences, Inc. (GILD) a Best Biotech Stock According to Billionaires? - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

7 Most Undervalued Biotech Stocks To Invest In - Insider Monkey

Mar 17, 2025
pulisher
Mar 17, 2025

GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell? - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Gilead SciencesWomen's History Month Celebrated With Its Team - CSRwire.com

Mar 17, 2025
pulisher
Mar 17, 2025

Is Gilead Sciences, Inc. (GILD) The Most Undervalued NASDAQ Stock To Buy According To Hedge Funds? - Insider Monkey

Mar 17, 2025
pulisher
Mar 16, 2025

Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally - Seeking Alpha

Mar 16, 2025
pulisher
Mar 14, 2025

Gilead's accounting chief hits the exit—Chutes & Ladders - Fierce Biotech

Mar 14, 2025
pulisher
Mar 13, 2025

Gilead Sciences: A rare Nasdaq gem with consistent returns across time horizons - The Financial Express

Mar 13, 2025
pulisher
Mar 13, 2025

Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy - Citeline News & Insights

Mar 13, 2025
pulisher
Mar 13, 2025

Is Gilead Sciences Gaining or Losing Market Support? - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey

Mar 13, 2025
pulisher
Mar 13, 2025

May 2nd Options Now Available For Gilead Sciences (GILD) - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

The Global Health Challenge of HIV and Hepatitis B Coinfections - Gilead Sciences

Mar 13, 2025
pulisher
Mar 13, 2025

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Gilead Sciences CFO sells $2.1 million in stock - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Gilead Pushes PrEP Envelope As ViiV Explores Self-Administered, Long-Acting Drugs - Citeline News & Insights

Mar 12, 2025
pulisher
Mar 12, 2025

Gilead Sciences announces executive departure and interim appointment By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Gilead Sciences announces executive departure and interim appointment - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Gilead Presents New HIV Treatment And Cure Research Data - AOL

Mar 12, 2025
pulisher
Mar 12, 2025

GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive - Zacks Investment Research

Mar 12, 2025

Gilead Sciences Inc (GILD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$58.60
price down icon 0.86%
drug_manufacturers_general PFE
$26.21
price down icon 0.38%
$315.75
price down icon 0.91%
drug_manufacturers_general NVS
$111.56
price down icon 0.59%
drug_manufacturers_general MRK
$94.02
price down icon 0.74%
大文字化:     |  ボリューム (24 時間):